Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Alzheon, Inc. has 3 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 3 distinct examiners and 3 distinct art units, so the available record shows a separate examination setting for each pending matter.
CARR, DEBORAH D is the busiest examiner, with 1 pending matter. Counsel should maintain individualized analyses of the cited art and claim scope while coordinating scientific terminology across the portfolio. The distributed assignments do not support relying on one examiner’s treatment as a direct guide for the other matters.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (33%) |
| No statute on record | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CARR, DEBORAH D | 1 | 81.8% | +2.9% |
| MARTINEZ, TARA L | 1 | 62.7% | +65.6% |
| GOLDBERG, JEANINE ANNE | 1 | 45.4% | +40.5% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17877380 | METHODS FOR TREATING NEUROLOGICAL DISORDERS | MARTINEZ, TARA L | 105d overdue |
| 17619398 | METHODS FOR TREATING NEURODEGENERATIVE DISORDERS | GOLDBERG, JEANINE ANNE | 6d |
| Art Unit | Apps |
|---|---|
| 1691 | 1 |
| 1654 | 1 |
| 1682 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18793452 | METHODS FOR TREATING NEURODEGENERATIVE DISORDERS | CARR, DEBORAH D | 1691 | Other | Final Rejection | — | Pending | Aug 02, 2024 |
| 17877380 | METHODS FOR TREATING NEUROLOGICAL DISORDERS | MARTINEZ, TARA L | 1654 | §103DP | Final Rejection | 105d overdue | Pending | Jul 29, 2022 |
| 17619398 | METHODS FOR TREATING NEURODEGENERATIVE DISORDERS | GOLDBERG, JEANINE ANNE | 1682 | Other | Final Rejection | 6d | Pending | Dec 15, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAlzheon, Inc. has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Deborah D Carr has the most, with 1 of Alzheon, Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
